CD68-ET3-LV-CD34+ gene therapy (Centre for Stem Cell Research/Institute For Stem Cell Biology & Regenerative Medicine)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCD68-ET3-LV-CD34+ gene therapy (Centre for Stem Cell Research/Institute For Stem Cell Biology & Regenerative Medicine)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionCoagulation factor VIII stimulants
TargetsCoagulation factor VIII
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChristian Medical College, Vellore
China Registration ClassN/A

Develop Information

Active CompaniesInstitute for Stem Cell and Regeneration Chinese Academy of SciencesChristian Medical College, Vellore
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A